| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Spermatozoa | 45 | 2015 | 200 | 8.540 |
Why?
|
| DNA | 30 | 2015 | 574 | 3.480 |
Why?
|
| Chromatin | 18 | 2015 | 169 | 3.120 |
Why?
|
| Nuclear Matrix | 15 | 2015 | 17 | 2.880 |
Why?
|
| Cell Nucleus | 26 | 2015 | 366 | 2.600 |
Why?
|
| DNA Replication | 11 | 2015 | 152 | 2.460 |
Why?
|
| DNA Fragmentation | 8 | 2015 | 92 | 2.200 |
Why?
|
| Origin Recognition Complex | 4 | 2017 | 23 | 2.020 |
Why?
|
| Zygote | 5 | 2016 | 39 | 1.970 |
Why?
|
| Deoxyribonucleases | 5 | 2009 | 25 | 1.430 |
Why?
|
| Meiosis | 3 | 2017 | 62 | 1.180 |
Why?
|
| DNA Topoisomerases, Type II | 5 | 2011 | 10 | 1.120 |
Why?
|
| Mice | 29 | 2017 | 5913 | 1.070 |
Why?
|
| Animals | 56 | 2017 | 15081 | 1.060 |
Why?
|
| Embryo, Mammalian | 7 | 2016 | 153 | 0.960 |
Why?
|
| Oocytes | 8 | 2011 | 146 | 0.940 |
Why?
|
| Sperm Injections, Intracytoplasmic | 8 | 2013 | 68 | 0.940 |
Why?
|
| Embryonic Development | 4 | 2013 | 76 | 0.930 |
Why?
|
| Male | 62 | 2015 | 20025 | 0.920 |
Why?
|
| Staphylococcal Infections | 2 | 2014 | 58 | 0.880 |
Why?
|
| Epididymis | 5 | 2015 | 28 | 0.840 |
Why?
|
| DNA Damage | 5 | 2015 | 352 | 0.800 |
Why?
|
| Egtazic Acid | 4 | 2009 | 13 | 0.790 |
Why?
|
| DNA-Binding Proteins | 5 | 2012 | 539 | 0.740 |
Why?
|
| Vas Deferens | 3 | 2015 | 6 | 0.730 |
Why?
|
| Cell Cycle Proteins | 2 | 2012 | 229 | 0.690 |
Why?
|
| Mice, Inbred DBA | 8 | 2016 | 71 | 0.680 |
Why?
|
| Chelating Agents | 2 | 2009 | 57 | 0.650 |
Why?
|
| Spermatogenesis | 3 | 2012 | 155 | 0.640 |
Why?
|
| Parthenogenesis | 2 | 2016 | 9 | 0.630 |
Why?
|
| Alu Elements | 2 | 2007 | 10 | 0.610 |
Why?
|
| DNA Breaks, Double-Stranded | 2 | 2013 | 35 | 0.550 |
Why?
|
| Dithiothreitol | 6 | 2013 | 18 | 0.550 |
Why?
|
| Protein Multimerization | 1 | 2017 | 103 | 0.550 |
Why?
|
| Cycloheximide | 1 | 2016 | 30 | 0.540 |
Why?
|
| Embryonic and Fetal Development | 3 | 2001 | 37 | 0.540 |
Why?
|
| Nuclear Proteins | 3 | 2012 | 307 | 0.540 |
Why?
|
| Mitosis | 2 | 2016 | 99 | 0.540 |
Why?
|
| Chromosomes | 5 | 2002 | 37 | 0.530 |
Why?
|
| Chromatin Assembly and Disassembly | 2 | 2015 | 43 | 0.510 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2014 | 15 | 0.490 |
Why?
|
| Academies and Institutes | 1 | 2014 | 37 | 0.490 |
Why?
|
| Sarcoma | 1 | 2014 | 10 | 0.490 |
Why?
|
| Gloves, Surgical | 1 | 2014 | 1 | 0.480 |
Why?
|
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2014 | 1 | 0.480 |
Why?
|
| Operating Rooms | 1 | 2014 | 4 | 0.480 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2014 | 6 | 0.480 |
Why?
|
| Staphylococcus | 1 | 2014 | 9 | 0.480 |
Why?
|
| Intraoperative Care | 1 | 2014 | 10 | 0.480 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2014 | 13 | 0.480 |
Why?
|
| Cricetinae | 11 | 2005 | 238 | 0.480 |
Why?
|
| Cross Infection | 1 | 2014 | 38 | 0.460 |
Why?
|
| Comet Assay | 1 | 2013 | 76 | 0.460 |
Why?
|
| Nucleic Acid Conformation | 8 | 2003 | 146 | 0.450 |
Why?
|
| Survivors | 1 | 2014 | 136 | 0.440 |
Why?
|
| Cell Fractionation | 1 | 2013 | 30 | 0.440 |
Why?
|
| Calcium Chloride | 2 | 2013 | 5 | 0.440 |
Why?
|
| Apoptosis | 2 | 2012 | 1398 | 0.410 |
Why?
|
| Calcium | 3 | 2009 | 480 | 0.400 |
Why?
|
| DNA, Superhelical | 1 | 2011 | 7 | 0.390 |
Why?
|
| Humans | 34 | 2022 | 37093 | 0.380 |
Why?
|
| Testis | 1 | 2012 | 187 | 0.380 |
Why?
|
| RNA-Binding Proteins | 1 | 2012 | 146 | 0.370 |
Why?
|
| Models, Biological | 7 | 2012 | 677 | 0.370 |
Why?
|
| Female | 19 | 2022 | 20969 | 0.370 |
Why?
|
| Biomedical Research | 1 | 2014 | 400 | 0.360 |
Why?
|
| Mice, Inbred C57BL | 6 | 2013 | 1609 | 0.350 |
Why?
|
| Genome | 3 | 2007 | 125 | 0.340 |
Why?
|
| Epigenesis, Genetic | 1 | 2010 | 219 | 0.320 |
Why?
|
| Proteins | 1 | 2011 | 369 | 0.310 |
Why?
|
| In Situ Hybridization, Fluorescence | 6 | 2001 | 53 | 0.310 |
Why?
|
| Short Interspersed Nucleotide Elements | 1 | 2007 | 4 | 0.310 |
Why?
|
| Detergents | 3 | 2002 | 24 | 0.310 |
Why?
|
| Expressed Sequence Tags | 1 | 2007 | 27 | 0.300 |
Why?
|
| DNA Breaks | 1 | 2006 | 4 | 0.290 |
Why?
|
| Financial Management, Hospital | 1 | 2006 | 4 | 0.290 |
Why?
|
| Databases, Genetic | 1 | 2007 | 93 | 0.290 |
Why?
|
| Efficiency, Organizational | 1 | 2006 | 14 | 0.290 |
Why?
|
| Quality Assurance, Health Care | 1 | 2006 | 56 | 0.280 |
Why?
|
| Biochemistry | 1 | 2006 | 13 | 0.280 |
Why?
|
| Histones | 4 | 2013 | 190 | 0.280 |
Why?
|
| Physiology | 1 | 2006 | 14 | 0.280 |
Why?
|
| Anatomy | 1 | 2006 | 24 | 0.270 |
Why?
|
| Chromosome Mapping | 4 | 1996 | 188 | 0.260 |
Why?
|
| Protamines | 5 | 2009 | 18 | 0.260 |
Why?
|
| Schools, Medical | 1 | 2006 | 198 | 0.240 |
Why?
|
| Urinary Bladder | 2 | 1995 | 29 | 0.230 |
Why?
|
| Mass Screening | 2 | 1998 | 462 | 0.230 |
Why?
|
| Edetic Acid | 3 | 2013 | 23 | 0.230 |
Why?
|
| Transgenes | 1 | 2002 | 59 | 0.220 |
Why?
|
| Chromosome Aberrations | 2 | 2002 | 60 | 0.220 |
Why?
|
| Prostatic Neoplasms | 5 | 1998 | 935 | 0.220 |
Why?
|
| Health Personnel | 2 | 2022 | 228 | 0.210 |
Why?
|
| Manganese Compounds | 2 | 2013 | 16 | 0.200 |
Why?
|
| Mentors | 1 | 2022 | 127 | 0.200 |
Why?
|
| Infertility, Male | 4 | 2007 | 45 | 0.190 |
Why?
|
| Cryptorchidism | 1 | 2000 | 3 | 0.190 |
Why?
|
| Chlorides | 2 | 2013 | 56 | 0.190 |
Why?
|
| Tissue Distribution | 3 | 2012 | 207 | 0.190 |
Why?
|
| Fertilization | 2 | 2012 | 38 | 0.190 |
Why?
|
| Octoxynol | 3 | 2006 | 19 | 0.190 |
Why?
|
| RNA, Ribosomal, 5S | 2 | 2001 | 3 | 0.190 |
Why?
|
| Genetic Code | 1 | 2000 | 7 | 0.180 |
Why?
|
| Mesocricetus | 5 | 2003 | 54 | 0.170 |
Why?
|
| Health Services for the Aged | 1 | 2019 | 20 | 0.170 |
Why?
|
| Physicians | 1 | 2021 | 163 | 0.170 |
Why?
|
| Multigene Family | 2 | 1996 | 106 | 0.160 |
Why?
|
| Liver Neoplasms, Experimental | 5 | 1986 | 23 | 0.160 |
Why?
|
| Genetic Variation | 2 | 2007 | 387 | 0.160 |
Why?
|
| Keratins | 4 | 1986 | 25 | 0.160 |
Why?
|
| Quality of Health Care | 1 | 2019 | 138 | 0.160 |
Why?
|
| Mice, Inbred Strains | 4 | 2002 | 116 | 0.150 |
Why?
|
| Enzyme Activation | 2 | 2009 | 444 | 0.150 |
Why?
|
| Cations, Divalent | 2 | 2008 | 24 | 0.150 |
Why?
|
| Prostate-Specific Antigen | 1 | 1998 | 118 | 0.150 |
Why?
|
| Telomere | 2 | 1996 | 56 | 0.140 |
Why?
|
| Abnormalities, Multiple | 1 | 2016 | 36 | 0.130 |
Why?
|
| Deoxyribonuclease I | 2 | 2007 | 25 | 0.130 |
Why?
|
| RNA, Ribosomal | 1 | 1995 | 25 | 0.130 |
Why?
|
| Genes | 1 | 1995 | 60 | 0.130 |
Why?
|
| Cost-Benefit Analysis | 3 | 2014 | 144 | 0.130 |
Why?
|
| Urethral Obstruction | 1 | 1995 | 1 | 0.130 |
Why?
|
| Elastin | 1 | 1995 | 40 | 0.130 |
Why?
|
| Catheter-Related Infections | 1 | 2014 | 11 | 0.120 |
Why?
|
| Hawaii | 2 | 2014 | 1929 | 0.120 |
Why?
|
| Research Support as Topic | 1 | 2014 | 80 | 0.120 |
Why?
|
| Orthopedic Procedures | 1 | 2014 | 10 | 0.120 |
Why?
|
| Sodium Dodecyl Sulfate | 1 | 2013 | 21 | 0.120 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1993 | 31 | 0.120 |
Why?
|
| Age Distribution | 1 | 2014 | 225 | 0.120 |
Why?
|
| Databases, Factual | 1 | 2014 | 291 | 0.110 |
Why?
|
| DNA Replication Timing | 1 | 2012 | 3 | 0.110 |
Why?
|
| Pregnancy | 2 | 2009 | 1549 | 0.110 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2013 | 133 | 0.110 |
Why?
|
| Rodentia | 1 | 2013 | 43 | 0.110 |
Why?
|
| Hydrogen Peroxide | 1 | 2013 | 190 | 0.110 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 1992 | 18 | 0.110 |
Why?
|
| Fertilization in Vitro | 3 | 2002 | 54 | 0.110 |
Why?
|
| Prognosis | 1 | 2014 | 739 | 0.100 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 1992 | 63 | 0.100 |
Why?
|
| Head | 1 | 2011 | 27 | 0.100 |
Why?
|
| Intensive Care Units | 2 | 2014 | 59 | 0.100 |
Why?
|
| Quaternary Ammonium Compounds | 2 | 2002 | 34 | 0.100 |
Why?
|
| Glycoside Hydrolases | 1 | 2011 | 6 | 0.100 |
Why?
|
| Poly Adenosine Diphosphate Ribose | 1 | 2011 | 3 | 0.100 |
Why?
|
| Universities | 1 | 2014 | 442 | 0.100 |
Why?
|
| Reaction Time | 1 | 2011 | 143 | 0.100 |
Why?
|
| Morphine | 1 | 2011 | 85 | 0.100 |
Why?
|
| Infant, Premature | 1 | 2011 | 129 | 0.100 |
Why?
|
| S Phase | 1 | 2011 | 37 | 0.090 |
Why?
|
| DNA Probes | 4 | 1996 | 29 | 0.090 |
Why?
|
| Social Behavior | 1 | 2011 | 131 | 0.090 |
Why?
|
| Analgesics, Opioid | 1 | 2011 | 197 | 0.090 |
Why?
|
| Aged, 80 and over | 2 | 2014 | 2379 | 0.090 |
Why?
|
| Protein Conformation | 1 | 2011 | 389 | 0.090 |
Why?
|
| Cells, Cultured | 1 | 2013 | 1518 | 0.090 |
Why?
|
| Microscopy, Electron | 2 | 2000 | 209 | 0.080 |
Why?
|
| Delivery of Health Care | 2 | 2022 | 276 | 0.080 |
Why?
|
| Mutation | 1 | 1994 | 1095 | 0.080 |
Why?
|
| Rats | 6 | 2011 | 3483 | 0.080 |
Why?
|
| Aged | 4 | 2014 | 6741 | 0.080 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2002 | 173 | 0.080 |
Why?
|
| GC Rich Sequence | 1 | 2007 | 3 | 0.080 |
Why?
|
| Microscopy, Fluorescence | 3 | 2002 | 252 | 0.080 |
Why?
|
| Chromosomes, Mammalian | 1 | 2007 | 18 | 0.080 |
Why?
|
| Calcium-Binding Proteins | 1 | 2008 | 76 | 0.080 |
Why?
|
| Databases, Nucleic Acid | 1 | 2007 | 27 | 0.080 |
Why?
|
| Adult | 5 | 2014 | 11712 | 0.080 |
Why?
|
| Aphidicolin | 1 | 2007 | 3 | 0.080 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2007 | 6 | 0.080 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 2007 | 28 | 0.070 |
Why?
|
| Program Evaluation | 2 | 2022 | 339 | 0.070 |
Why?
|
| Adolescent | 3 | 2014 | 5363 | 0.070 |
Why?
|
| Crosses, Genetic | 1 | 2007 | 48 | 0.070 |
Why?
|
| Sequence Deletion | 1 | 2007 | 87 | 0.070 |
Why?
|
| Poly A | 1 | 2007 | 33 | 0.070 |
Why?
|
| Organizational Case Studies | 1 | 2006 | 29 | 0.070 |
Why?
|
| Extracellular Fluid | 1 | 2006 | 13 | 0.070 |
Why?
|
| Sodium Chloride | 1 | 2006 | 55 | 0.070 |
Why?
|
| Immunoblotting | 1 | 2006 | 176 | 0.070 |
Why?
|
| Cryopreservation | 2 | 2004 | 25 | 0.070 |
Why?
|
| Internet | 1 | 2007 | 211 | 0.070 |
Why?
|
| Genomics | 1 | 2007 | 223 | 0.070 |
Why?
|
| Manganese | 1 | 2006 | 87 | 0.070 |
Why?
|
| Texas | 1 | 2006 | 324 | 0.060 |
Why?
|
| Karyotyping | 2 | 2002 | 47 | 0.060 |
Why?
|
| Blastocyst | 2 | 2002 | 48 | 0.060 |
Why?
|
| Promoter Regions, Genetic | 1 | 2007 | 515 | 0.060 |
Why?
|
| Substrate Specificity | 1 | 2005 | 212 | 0.060 |
Why?
|
| United States | 3 | 2022 | 4223 | 0.060 |
Why?
|
| Intermediate Filament Proteins | 1 | 1984 | 13 | 0.060 |
Why?
|
| Young Adult | 1 | 2014 | 4268 | 0.060 |
Why?
|
| Prostheses and Implants | 1 | 2003 | 15 | 0.060 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 2003 | 27 | 0.060 |
Why?
|
| Fertility | 1 | 2004 | 59 | 0.060 |
Why?
|
| Neoplasms | 1 | 1994 | 1103 | 0.060 |
Why?
|
| Bone Neoplasms | 1 | 2003 | 45 | 0.060 |
Why?
|
| Chromosome Breakage | 1 | 2002 | 14 | 0.060 |
Why?
|
| Indicators and Reagents | 1 | 2002 | 58 | 0.050 |
Why?
|
| Reducing Agents | 1 | 2002 | 13 | 0.050 |
Why?
|
| Organ Culture Techniques | 1 | 2002 | 103 | 0.050 |
Why?
|
| Sperm Head | 1 | 2002 | 10 | 0.050 |
Why?
|
| Middle Aged | 3 | 2014 | 10129 | 0.050 |
Why?
|
| Sperm-Ovum Interactions | 1 | 2002 | 13 | 0.050 |
Why?
|
| Faculty, Medical | 1 | 2022 | 66 | 0.050 |
Why?
|
| Microinjections | 2 | 1999 | 57 | 0.050 |
Why?
|
| Drug Synergism | 1 | 2002 | 177 | 0.050 |
Why?
|
| Faculty | 1 | 2022 | 94 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 2 | 2002 | 661 | 0.050 |
Why?
|
| Interprofessional Relations | 1 | 2021 | 54 | 0.050 |
Why?
|
| Mice, Transgenic | 1 | 2002 | 617 | 0.050 |
Why?
|
| Phenylmethylsulfonyl Fluoride | 1 | 2000 | 3 | 0.050 |
Why?
|
| Embryo Transfer | 1 | 2000 | 33 | 0.040 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 4 | 1989 | 201 | 0.040 |
Why?
|
| Stem Cells | 1 | 2001 | 141 | 0.040 |
Why?
|
| Nuclear Transfer Techniques | 1 | 1999 | 15 | 0.040 |
Why?
|
| Transfection | 1 | 2000 | 523 | 0.040 |
Why?
|
| Protein Structure, Tertiary | 1 | 2000 | 408 | 0.040 |
Why?
|
| Disulfides | 1 | 1999 | 77 | 0.040 |
Why?
|
| Prostatectomy | 1 | 1998 | 63 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2001 | 587 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2019 | 187 | 0.040 |
Why?
|
| Oxidation-Reduction | 1 | 1999 | 431 | 0.040 |
Why?
|
| Risk | 1 | 1997 | 267 | 0.030 |
Why?
|
| Ethanol | 1 | 1998 | 192 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 1996 | 129 | 0.030 |
Why?
|
| Fluorescent Dyes | 1 | 1996 | 181 | 0.030 |
Why?
|
| Tropoelastin | 1 | 1995 | 13 | 0.030 |
Why?
|
| Catheterization, Central Venous | 1 | 2014 | 6 | 0.030 |
Why?
|
| Decision Trees | 1 | 2014 | 19 | 0.030 |
Why?
|
| Guinea Pigs | 1 | 1995 | 145 | 0.030 |
Why?
|
| Organ Size | 1 | 1995 | 157 | 0.030 |
Why?
|
| Cisplatin | 2 | 1986 | 72 | 0.030 |
Why?
|
| Nucleosomes | 1 | 1994 | 29 | 0.030 |
Why?
|
| Eukaryotic Cells | 1 | 1994 | 36 | 0.030 |
Why?
|
| Blotting, Southern | 2 | 1990 | 69 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2014 | 77 | 0.030 |
Why?
|
| Deoxyribonuclease EcoRI | 1 | 1993 | 5 | 0.030 |
Why?
|
| Molecular Structure | 1 | 1996 | 492 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2011 | 661 | 0.030 |
Why?
|
| Fibroblasts | 1 | 1995 | 272 | 0.030 |
Why?
|
| Models, Genetic | 1 | 1994 | 172 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 1996 | 578 | 0.030 |
Why?
|
| Cystoscopy | 1 | 1992 | 4 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 1997 | 358 | 0.030 |
Why?
|
| Urine | 1 | 1992 | 13 | 0.030 |
Why?
|
| Liver | 1 | 1995 | 479 | 0.030 |
Why?
|
| Centrifugation, Density Gradient | 2 | 1989 | 22 | 0.030 |
Why?
|
| Diagnostic Imaging | 1 | 1992 | 53 | 0.030 |
Why?
|
| Genetic Markers | 1 | 1992 | 142 | 0.030 |
Why?
|
| Biopsy | 1 | 1992 | 164 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 1992 | 275 | 0.030 |
Why?
|
| Rats, Inbred Strains | 3 | 1986 | 133 | 0.020 |
Why?
|
| Base Sequence | 1 | 1993 | 997 | 0.020 |
Why?
|
| Receptors, Adrenergic, alpha | 1 | 1990 | 18 | 0.020 |
Why?
|
| Restriction Mapping | 1 | 1990 | 45 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 1990 | 8 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 1990 | 6 | 0.020 |
Why?
|
| Child | 2 | 2011 | 3131 | 0.020 |
Why?
|
| Sonication | 1 | 1989 | 16 | 0.020 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1989 | 142 | 0.020 |
Why?
|
| Brain Chemistry | 1 | 1989 | 140 | 0.020 |
Why?
|
| Cross-Linking Reagents | 2 | 1986 | 51 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2011 | 894 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2011 | 885 | 0.020 |
Why?
|
| Brain | 1 | 1995 | 1346 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2011 | 1418 | 0.020 |
Why?
|
| Molecular Weight | 2 | 1984 | 167 | 0.020 |
Why?
|
| Chromates | 1 | 1986 | 2 | 0.020 |
Why?
|
| Potassium Compounds | 1 | 1986 | 4 | 0.020 |
Why?
|
| Succinimides | 1 | 1985 | 10 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 1986 | 92 | 0.020 |
Why?
|
| Nucleoproteins | 1 | 1985 | 11 | 0.020 |
Why?
|
| Urea | 1 | 1985 | 41 | 0.020 |
Why?
|
| Chromium | 1 | 1985 | 27 | 0.020 |
Why?
|
| Macromolecular Substances | 1 | 1985 | 96 | 0.020 |
Why?
|
| Antigens | 1 | 1984 | 56 | 0.020 |
Why?
|
| Femoral Neoplasms | 1 | 2003 | 1 | 0.010 |
Why?
|
| Humerus | 1 | 2003 | 2 | 0.010 |
Why?
|
| Reoperation | 1 | 2003 | 24 | 0.010 |
Why?
|
| Antigens, Neoplasm | 1 | 1984 | 59 | 0.010 |
Why?
|
| Kidney Neoplasms | 1 | 2003 | 68 | 0.010 |
Why?
|
| Haploidy | 1 | 2002 | 16 | 0.010 |
Why?
|
| Genetic Techniques | 1 | 2002 | 15 | 0.010 |
Why?
|
| Disease Progression | 1 | 2003 | 601 | 0.010 |
Why?
|
| Protein Binding | 1 | 1984 | 972 | 0.010 |
Why?
|
| Azure Stains | 1 | 1998 | 1 | 0.010 |
Why?
|
| Chromosome Disorders | 1 | 1998 | 9 | 0.010 |
Why?
|
| Survival Rate | 1 | 1998 | 311 | 0.010 |
Why?
|
| Population Surveillance | 1 | 1998 | 238 | 0.010 |
Why?
|
| Cell Survival | 1 | 1998 | 864 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2003 | 1502 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1990 | 28 | 0.010 |
Why?
|
| Genes, Tumor Suppressor | 1 | 1990 | 63 | 0.010 |
Why?
|
| Chromosome Deletion | 1 | 1990 | 56 | 0.010 |
Why?
|
| Alleles | 1 | 1990 | 321 | 0.010 |
Why?
|
| Lamins | 1 | 1985 | 5 | 0.000 |
Why?
|
| Immunoenzyme Techniques | 1 | 1984 | 108 | 0.000 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1984 | 189 | 0.000 |
Why?
|
| Kinetics | 1 | 1986 | 708 | 0.000 |
Why?
|
| Antibodies, Monoclonal | 1 | 1984 | 290 | 0.000 |
Why?
|
| Cell Line | 1 | 1984 | 1354 | 0.000 |
Why?
|